Epkinly fails its first confirmatory test
And that could affect the drug's third-line accelerated approval.
J&J claims another second-line Tecvayli win
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
Revolution shows its selective hand
The company will start three phase 3 trials of its G12D project this year.
ImmunityBio gets lung cancer boost
But PFS data are lacking, and there are questions about first and second-line plans.
RAS buzz lifts Erasca
But the company still has a lot to prove with ERAS-0015.
No checkpoint glory for Acrivon
Prexasertib data worsen again, and biomarkers are up in the air.
ASCO-GI – Astellas makes a case for its Vyloy triplet
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
Different dosing enlivens Enliven’s share price
ELVN-001 is made to look more like Terns’ TERN-701.
ASCO-GI – Astellas focuses on a degrader-chemo combo
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
